Literature DB >> 12710203

Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine.

Jacquelyn A Hank1, Jean E Surfus, Jacek Gan, Amy Ostendorf, Stephen D Gillies, Paul M Sondel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12710203     DOI： 10.1385/1-59259-380-1:123

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN： 1543-1894


× No keyword cloud information.
  9 in total

1.  Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

Authors:  Fariba Navid; Paul M Sondel; Raymond Barfield; Barry L Shulkin; Robert A Kaufman; Jim A Allay; Jacek Gan; Paul Hutson; Songwon Seo; Kyungmann Kim; Jacob Goldberg; Jacquelyn A Hank; Catherine A Billups; Jianrong Wu; Wayne L Furman; Lisa M McGregor; Mario Otto; Stephen D Gillies; Rupert Handgretinger; Victor M Santana
Journal:  J Clin Oncol       Date:  2014-04-07       Impact factor: 44.544

2.  Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.

Authors:  Ilia N Buhtoiarov; Zane C Neal; Jacek Gan; Tatiana N Buhtoiarova; Manish S Patankar; Jennifer A A Gubbels; Jacquelyn A Hank; Brett Yamane; Alexander L Rakhmilevich; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
Journal:  J Leukoc Biol       Date:  2011-01-19       Impact factor: 4.962

3.  Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma.

Authors:  Rosa Nguyen; Xiyuan Zhang; Ming Sun; Shahroze Abbas; Charlie Seibert; Michael C Kelly; Jack F Shern; Carol J Thiele
Journal:  Clin Cancer Res       Date:  2022-09-01       Impact factor: 13.801

4.  Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.

Authors:  David M King; Mark R Albertini; Heidi Schalch; Jacquelyn A Hank; Jacek Gan; Jean Surfus; David Mahvi; Joan H Schiller; Thomas Warner; KyungMann Kim; Jens Eickhoff; Kari Kendra; Ralph Reisfeld; Stephen D Gillies; Paul Sondel
Journal:  J Clin Oncol       Date:  2004-10-13       Impact factor: 44.544

5.  Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.

Authors:  Jacquelyn A Hank; Jacek Gan; Hyunji Ryu; Amy Ostendorf; Michael C Stauder; Adam Sternberg; Mark Albertini; Kin-Ming Lo; Stephen D Gillies; Jens Eickhoff; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

6.  A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.

Authors:  Kaci L Osenga; Jacquelyn A Hank; Mark R Albertini; Jacek Gan; Adam G Sternberg; Jens Eickhoff; Robert C Seeger; Katherine K Matthay; C Patrick Reynolds; Clare Twist; Mark Krailo; Peter C Adamson; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

7.  A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.

Authors:  Sara M Federico; M Beth McCarville; Barry L Shulkin; Paul M Sondel; Jacquelyn A Hank; Paul Hutson; Michael Meagher; Aaron Shafer; Catherine Y Ng; Wing Leung; William E Janssen; Jianrong Wu; Shenghua Mao; Rachel C Brennan; Victor M Santana; Alberto S Pappo; Wayne L Furman
Journal:  Clin Cancer Res       Date:  2017-09-22       Impact factor: 12.531

8.  Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma.

Authors:  Jacob L Goldberg; Fariba Navid; Jacqueline A Hank; Amy K Erbe; Victor Santana; Jacek Gan; Fenna de Bie; Amal M Javaid; Anna Hoefges; Michael Merdler; Lakeesha Carmichael; KyungMann Kim; Michael W Bishop; Michael M Meager; Steven D Gillies; Janardan P Pandey; Paul M Sondel
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751

9.  A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors.

Authors:  Michael W Bishop; Paul R Hutson; Jacquelyn A Hank; Paul M Sondel; Wayne L Furman; Michael M Meagher; Fariba Navid; Victor M Santana
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.